## Exhibit F



Deposition of: **Sanjeeva Kalva**, **M.D.** 

July 11, 2017

In the Matter of:

In Re: Bard IVC Filters Products Liability

Veritext Legal Solutions

1075 Peachtree St. NE , Suite 3625 Atlanta, GA, 30309 800.808.4958 | calendar-atl@veritext.com | 770.343.9696

	Page 8
1	copy of that?
2	A. No. This is the first time I'm seeing this
3	one.
4	Q. Were you asked to bring any materials with
5	you to the deposition today?
6	A. I brought something. I brought my CV. I
7	updated it from a recent lecture I gave yester- not
8	yesterday. That was on Sunday morning. So I updated
9	it since March. And I think one of the papers were
10	published after March. I think I updated those things
11	also. And I gave a lecture to residents and fellows.
12	That was also updated in the CV.
13	Q. What else did you bring with you today?
14	A. The next one is our expert report that was
15	submitted before
16	Q. Okay.
17	A I have a copy of that. And then
18	MR. NORTH: May I keep this one?
19	MR. JOHNSON: Sure, you can.
20	MR. NORTH: Okay.
21	MR. JOHNSON: I'll give it back to you
22	once you go through everything.
23	MR. NORTH: Oh, okay.
24	A. Okay. And this is the David Kessler's
25	report that we read and heavily relied on. And

	Page 24
1	I removed Denali. So I have removed all of them but
2	may not have implanted each one of them.
3	Q. Now, you're obviously an expert in
4	interventional radiology, correct?
5	A. I believe so.
6	Q. You would agree that you're not an engineer,
7	however?
8	A. By training I'm not an engineer. By
9	training I'm a medical person. I have studied
10	medicine, and I became interventional radiologist. I
11	do not have the same engineering background as an
12	engineer would have, if that's the question you're
13	trying to the question. But do I understand some
14	of the concepts? I do.
15	Q. You do not have any prior experience in the
16	design of inferior vena cava filters, do you?
17	A. Can you rephrase what exactly you mean by
18	that?
19	Q. Do you have any prior experience in
20	designing inferior vena cava filters?
21	A. You mean personally?
22	Q. Yes.
23	A. So I can tell that, mainly because I am
24	behind the scenes, I have ideas of new filter and that
25	I have not a patent. Yes, I did think about it, but I

Veritext Legal Solutions

Page 25

have not officially taken patented so far.

1

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

2.2

23

24

2.5

- Q. You are not a regulatory expert, are you?
- A. What do you mean by that?
- Q. An expert in FDA regulations.
- A. I'm not expert in the FDA regulations, but I know some of the regulations that they impose on physicians how the hospital function. I know those things, but I do not consider myself expert in designing or creating or implementing FDA regulations.
  - O. Do you consider yourself an epidemiologist?
- A. All medical doctors are -- learn about epidemiology as a part of their medicine. And if you look into any book chapter, any textbook, the first paragraph is always about the epidemiology of the disease. Epidemiology plays a significant role on our understanding of the disease, how resources are distributed.

So epidemiology is learned routinely throughout medicine. So the word epidemiologist is a different question who actually conducts or gets information about epidemiological conditions of a disease process or treatment aspects. But I'm not an epidemiologist, if you're talking about that. But I understand epidemiology is part and parcel of medicine that we learn every day. We practice medicine that

Page 28 1 So, yes, I consider myself an expert in ethics 2 because we conduct so many (unintelligible) studies. 3 If you look at my CV, I have more than a hundred (unintelligible) studies. And most of them 4 5 involve regulation, ethics training. But matter of fact, we undergo formal ethics training in medicine to 6 7 conduct research. It's a very rigorous process. 8 And a certification program goes 9 through, and we are asked to retake it multiple times 10 throughout our life just to make sure that we are up 11 to date with the changes both in the regulation and 12 also the basic ethical practice of research in 13 medicine. So, yes, I am expert in ethics. You read a number of Bard's internal 14 Ο. 15 documents as a part of your work in this case, 16 correct? 17 Α. That is correct. 18 0. Prior to your involvement in this 19 litigation, have you ever had an instance 2.0 professionally to read a manufacturer's internal 21 documents as a part of your work? 2.2 Α. No. Except for the IFUs that come on the products, I have not been exposed to internal 2.3 24 documents. I wish I was, to know the truth. unfortunately they were not communicated with me. 2.5

Veritext Legal Solutions 770,343,9696

Page 29

Q. And so throughout your professional career, this is the first time you have looked at or analyzed internal company documents from a manufacturer, correct?

MR. JOHNSON: Form.

A. That is correct.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

2.2

2.3

24

2.5

- Q. Have you ever participated in the design of an inferior vena cava filter?
- A. As I said, I can't disclose confidential information, as I am designing, myself, a filter. And I can't tell other parties involved in the process.

  Yes, I am. And -- and we have -- in addition to my one design, I have contributed to the knowledge of other companies who ask my opinion and my feeling about certain designs.

Yes, I did talk to intellectual people or engineers of different companies about what my feeling is about the design. I can't tell which company it is. I have provided very detailed aspects of the design which we thought are good, which we thought are very, very bad for those companies.

Q. So, if I understand what you're saying, you are at present, although you can't disclose the details, involved in designing a potential inferior vena cava filter?

Page 30 1 Α. That is correct. 2 Is it fair to assume that you believe that Q. 3 filters are an appropriate medical treatment for 4 certain indicated patients? 5 MR. JOHNSON: Form objection. So that's a good question. That's a very 6 7 loaded question too. We had a process to make it more 8 clear. One is, as you correctly pointed out, we had 9 to be very designate -- or very clear about what are 10 the indications, who are getting it, what are the 11 risk/benefit of any device we are placing on those 12 filters. 13 So, if appropriately used in certain 14 specific patient population, they are known to decrease the incidence of pulmonary embolism but not 15 16 necessarily the lives of the patient. 17 The famous study by Decursis (phonetic) published long time ago. He published first somewhere 18 19 And after it, he published one more in late 2000. 2.0 That is the basis of very, very excellent 21 study that showed whether IVC filters really have any 2.2 significant impact on the lives. 23 According to that study, at least what 24 I understand, I remember -- I may be -- I may have to look back at the paper -- IVC filters do not improve 25

Veritext Legal Solutions

	Page 52
1	but it would fill up my bag. It took hours of my
2	time, and it was really high.
3	Q. If I could ask you to look at Exhibit 4,
4	your report, and look at Schedule 1.
5	A. Yes.
6	Q. Who prepared Schedule 1?
7	A. As I recall, it was prepared on our behest,
8	or at least Kinney told (unintelligible) to prepare
9	the comments on our the so we can reference back
10	quickly. But we read all these documents. We all
11	claim them, so I don't know how you can
12	Q. Who prepared the document? Did lawyers
13	prepare that document?
14	A. That schedule?
15	Q. Yes.
16	A. Yes.
17	Q. Do you know which lawyers?
18	A. I don't know.
19	Q. Did you talk to the lawyers about the
20	preparation of that document, Schedule 1?
21	A. Both Kinney and I mentioned to them it would
22	be a good idea to have references tabulated
23	THE REPORTER: I can't understand you.
24	MR. NORTH: References.
25	A. These references are tabulated, as far as

Veritext Legal Solutions

	Page 53
1	quick references so they are in one location. You
2	don't have to go back to full articles every time. So
3	the idea was was to have a simple simplified
4	tabular form in one location.
5	Most of it was outlined in the original
6	document and actually physically underlined,
7	everything. I don't know where they are right now. I
8	can
9	Q. So someone prepared Schedule 1, some lawyers
LO	did, and presented it to you and your colleagues?
L1	A. We told them to prepare the way we want
L2	them.
L3	Q. Look at Schedule 2, if you would.
L4	Schedule 2 is entitled, Bard Employees
L5	Testifying Regarding the Use of SIR Article Quality
L6	Improvement Guidelines, correct?
L7	A. That is correct. That's what it says.
L8	Q. And it has quotations from various
L9	depositions of Bard employees, correct?
20	A. That is correct.
21	Q. And was this also prepared by a law firm?
22	A. Yes. And we did read we did look into
23	all those documents, and I have actually physically
24	viewed all the depositions of employees, which were
25	provided to me. And I did those things. And these

Veritext Legal Solutions 770.343.9696

Page 54 were just a list of many things that we told them to 1 2. prepare, so --3 So you have read each of these depositions Ο. in their entirety? 4 5 MR. JOHNSON: Form. 6 Α. Some in entirety. For example, Grassi, I 7 Some not entire. Some I did not read whole thing. read, but some I listened into it. For example, many 8 of the employees had a video deposition. So instead 9 10 of reading the text, I actually listened into them. 11 But everything that is written here is -- I have 12 looked into those documents. 13 Ο. Then there appear to be two different Schedule 5's. I think that Schedule 3 --14 15 Α. That was a mistake. 16 -- was mistakenly listed as Schedule 5. 0. 17 Yeah, that is true. Α. 18 And the first Schedule 5 is entitled, 0. 19 Supporting Testimony From Bard Employees on the 20 Importance of Providing Pertinent Information to Physicians For Making a Risk/Benefit Determination, 21 2.2 correct? 23 You mean this (indicating)? Α. That's the other, the second Schedule 2.4 O. No. 5. 2.5

Veritext Legal Solutions 770,343,9696

	Page 55
1	MR. JOHNSON: The first Schedule 5,
2	which should be Schedule 3.
3	A. Where it says, yeah, something. Let me see.
4	MR. JOHNSON: They're upside down.
5	THE WITNESS: Yeah, that was confusing.
6	MR. JOHNSON: Yeah.
7	BY MR. NORTH:
8	Q. Okay. That's the first Schedule 5 which, in
9	reality, I believe, was intended to be Schedule 3.
10	A. I believe so.
11	Q. Is entitled, Supporting Testimony from Bard
12	Employees on the Importance of Providing Pertinent
13	Information to Physicians For Making a Risk/Benefit
14	Determination, correct?
15	A. Yes, it says that.
16	Q. And this, again, was prepared by attorneys,
17	correct?
18	A. That is correct.
19	Q. Did you personally review each and every
20	deposition listed there?
21	A. I reviewed the deposition of Natalie Wong
22	completely, and I also reconfirmed may of the things
23	combined in the portions of
24	THE REPORTER: What, Doctor?
25	A. I have read Natalie Wong's deposition. And

Veritext Legal Solutions 770.343.9696

	Page 56
1	some of them are in video format. I listened to all
2	of them. Some which are not in the video format and
3	some I have not completely read, I have each
4	paragraph I have to look at the deposition to make
5	sure that actually that's what it says.
6	MR. JOHNSON: Slow down a little bit.
7	THE WITNESS: I'm sorry.
8	Q. So, if a deposition was available by
9	videotape
10	A. Uh-huh.
11	Q you would listen to the videotape instead
12	of reading the transcript?
13	A. Yeah.
14	Q. Okay.
15	A. Why not? That way I can
16	Q. Let's look at Schedule 4.
17	I get to ask the questions, not you.
18	(Laughter.)
19	Q. Schedule 4.
20	A. I'm sorry. I didn't mean to
21	MR. JOHNSON: But you can ask for
22	clarification.
23	A. Yeah, I didn't mean to say that. I'm a good
24	guy.
25	Q. Schedule 4, Involvement With IVC Filters?

Veritext Legal Solutions 770.343.9696

	Page 58
1	A. That is correct. And these are the things
2	we reviewed, everything.
3	Q. So you reviewed each of these documents
4	listed?
5	A. Uh-huh.
6	Q. I'm sorry, you've got to answer
7	A. Yes.
8	Q yes or no.
9	A. Sorry. Yes.
10	Q. But you did not make the choice of which
11	documents would be included in this schedule, did you?
12	MR. JOHNSON: Form.
13	A. What were provided to us, many of them we
14	reviewed. Actually, most of them we reviewed. And
15	whatever we felt pertinent, we told them, Please look.
16	This is what it is, this is what it is.
17	Obviously there are more than what I'm
18	exposed to. There are other things which I don't
19	know, I don't know. Whatever were given to me, I have
20	looked at them. And then that's what the
21	documentation says. I cannot tell things that I'm not
22	given to.
23	Q. And I guess that's my point. You were not
24	given all of the documents produced in this
25	litigation, were you?

Page 117

promise him that they would do a longitudinal study before releasing that device into market.

2.0

2.2

2.5

So my assumption was that they should have done it. And they didn't do it, according to what I know now. And when they -- when they knew some problem existed and we are telling them the problem is still present, a reasonable physician, reasonable person, ethical person would do -- let us go and fix it. Let us go and find the problem. Let us do something to fix what is happening there. And that was not present anywhere.

It was more of, If I -- if I do the study, I may fail or I may lose. They're looking at what is lost to the company rather than the patient's safety that is of paramount importance to us.

So as a company, as an individual working for a company, the person who wrote this email didn't express any concern for the patients who are suffering because of the device they manufactured.

So that bothers me. It doesn't bother you? Somebody having a -- somebody tell me, I don't really care what happens to you. You already got the filter. So that really bothered me. We are not caring for patients there.

Patients are the essence, and as human